Latest news with #JenniferBath
Business Wire
21-05-2025
- Business
- Business Wire
ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts
AUSTIN, Texas--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) a leader in AI-driven biotherapeutics, today announced it has engaged CORE IR, a strategic investor and public relations firm, to support the Company's ongoing investor relations and communications initiatives. CORE IR specializes in working with emerging and established growth companies to enhance investor awareness, strengthen shareholder engagement, and broaden outreach to various institutional and retail audiences. 'This collaboration with CORE IR represents an important step in IPA's ongoing commitment to improving our communication with the investment community and increasing market visibility,' said Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies. 'As we continue to execute on our growth strategy and expand our global capabilities, we believe CORE IR's expertise will help us better articulate our value proposition to existing and prospective shareholders.' Under the terms of the engagement, CORE IR will provide a comprehensive suite of investor relations services including strategic messaging, investor outreach, and support for IPA's communication programs. 'We are excited to work alongside the team at IPA,' said Scott Gordon, Co-Founder and President of CORE IR. 'IPA has established itself as a pioneering force in the antibody discovery and development space. We look forward to helping the company increase its engagement with the broader investment community.' About ImmunoPrecise Antibodies Ltd. ImmunoPrecise Antibodies Ltd. is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the discovery and development of therapeutic antibodies and is known for solving complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the 'IPA Family'). For more information, visit About CORE IR CORE IR is a strategic communications firm specializing in investor and public relations services. The firm supports public and private companies across a wide range of industries with customized programs to enhance corporate visibility, engage stakeholders, and support business objectives.
Yahoo
21-05-2025
- Business
- Yahoo
ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts
AUSTIN, Texas, May 21, 2025--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) a leader in AI-driven biotherapeutics, today announced it has engaged CORE IR, a strategic investor and public relations firm, to support the Company's ongoing investor relations and communications initiatives. CORE IR specializes in working with emerging and established growth companies to enhance investor awareness, strengthen shareholder engagement, and broaden outreach to various institutional and retail audiences. "This collaboration with CORE IR represents an important step in IPA's ongoing commitment to improving our communication with the investment community and increasing market visibility," said Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies. "As we continue to execute on our growth strategy and expand our global capabilities, we believe CORE IR's expertise will help us better articulate our value proposition to existing and prospective shareholders." Under the terms of the engagement, CORE IR will provide a comprehensive suite of investor relations services including strategic messaging, investor outreach, and support for IPA's communication programs. "We are excited to work alongside the team at IPA," said Scott Gordon, Co-Founder and President of CORE IR. "IPA has established itself as a pioneering force in the antibody discovery and development space. We look forward to helping the company increase its engagement with the broader investment community." About ImmunoPrecise Antibodies Ltd. ImmunoPrecise Antibodies Ltd. is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the discovery and development of therapeutic antibodies and is known for solving complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the "IPA Family"). For more information, visit About CORE IR CORE IR is a strategic communications firm specializing in investor and public relations services. The firm supports public and private companies across a wide range of industries with customized programs to enhance corporate visibility, engage stakeholders, and support business objectives. View source version on Contacts Investor Relations Louie Toma, CPA, CFAManaging Director investors@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
21-05-2025
- Business
- Associated Press
ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts
AUSTIN, Texas--(BUSINESS WIRE)--May 21, 2025-- ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) a leader in AI-driven biotherapeutics, today announced it has engaged CORE IR, a strategic investor and public relations firm, to support the Company's ongoing investor relations and communications initiatives. CORE IR specializes in working with emerging and established growth companies to enhance investor awareness, strengthen shareholder engagement, and broaden outreach to various institutional and retail audiences. 'This collaboration with CORE IR represents an important step in IPA's ongoing commitment to improving our communication with the investment community and increasing market visibility,' said Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies. 'As we continue to execute on our growth strategy and expand our global capabilities, we believe CORE IR's expertise will help us better articulate our value proposition to existing and prospective shareholders.' Under the terms of the engagement, CORE IR will provide a comprehensive suite of investor relations services including strategic messaging, investor outreach, and support for IPA's communication programs. 'We are excited to work alongside the team at IPA,' said Scott Gordon, Co-Founder and President of CORE IR. 'IPA has established itself as a pioneering force in the antibody discovery and development space. We look forward to helping the company increase its engagement with the broader investment community.' About ImmunoPrecise Antibodies Ltd. ImmunoPrecise Antibodies Ltd. is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the discovery and development of therapeutic antibodies and is known for solving complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the 'IPA Family'). For more information, visit About CORE IR CORE IR is a strategic communications firm specializing in investor and public relations services. The firm supports public and private companies across a wide range of industries with customized programs to enhance corporate visibility, engage stakeholders, and support business objectives. View source version on CONTACT: Investor Relations Louie Toma, CPA, CFA Managing [email protected] KEYWORD: UNITED STATES NORTH AMERICA CANADA TEXAS INDUSTRY KEYWORD: TECHNOLOGY INFECTIOUS DISEASES PUBLIC RELATIONS/INVESTOR RELATIONS COMMUNICATIONS HEALTH TECHNOLOGY SOFTWARE BIOTECHNOLOGY PHARMACEUTICAL HEALTH ARTIFICIAL INTELLIGENCE SOURCE: ImmunoPrecise Antibodies Ltd. Copyright Business Wire 2025. PUB: 05/21/2025 08:49 AM/DISC: 05/21/2025 08:48 AM
National Post
20-05-2025
- Business
- National Post
ImmunoPrecise Antibodies (IPA) to Present at Maxim Group's 2025 Virtual Tech Conference
Article content Article content AUSTIN, Texas — ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) a leader in AI-driven biotherapeutics, today announced that Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies Ltd., will be presenting at the Maxim Group's virtual conference: Article content The rapid evolution of technology is paving the way for disruption across all industries, including healthcare, drones, consumer IoT, business solutions, gaming & entertainment, and more. In Maxim's 2025 Virtual Tech Conference, we will explore how emerging growth companies are expanding their use of Quantum Computing and Artificial Intelligence (AI) to position themselves for the future. Maxim Senior Analysts will facilitate engaging dialogues with CEOs and key management of diverse companies who have their attention on technology and how it will impact and grow their business. Article content This conference will be live on M-Vest. To attend, sign up to become an M-Vest member in the above registration link. Article content About Maxim Group LLC Article content Maxim Group LLC is a full-service investment banking, securities and wealth management firm headquartered in New York. The Firm provides a full array of financial services including investment banking; private wealth management; and global institutional equity, fixed-income and derivatives sales & trading, equity research and prime brokerage services. Maxim Group is a registered broker-dealer with the U.S. Securities and Exchange Commission (SEC) and the Municipal Securities Rulemaking Board (MSRB) and is a member of FINRA SIPC, and NASDAQ. To learn more about Maxim Group, visit Article content ImmunoPrecise Antibodies Ltd. is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the discovery and development of therapeutic antibodies and is known for solving complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the 'IPA Family'). Article content Article content Article content Article content Contacts Article content Article content Article content
Associated Press
20-05-2025
- Business
- Associated Press
ImmunoPrecise Antibodies (IPA) to Present at Maxim Group's 2025 Virtual Tech Conference
AUSTIN, Texas--(BUSINESS WIRE)--May 20, 2025-- ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) a leader in AI-driven biotherapeutics, today announced that Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies Ltd., will be presenting at the Maxim Group's virtual conference: The rapid evolution of technology is paving the way for disruption across all industries, including healthcare, drones, consumer IoT, business solutions, gaming & entertainment, and more. In Maxim's 2025 Virtual Tech Conference, we will explore how emerging growth companies are expanding their use of Quantum Computing and Artificial Intelligence (AI) to position themselves for the future. Maxim Senior Analysts will facilitate engaging dialogues with CEOs and key management of diverse companies who have their attention on technology and how it will impact and grow their business. This conference will be live on M-Vest. To attend, sign up to become an M-Vest member in the above registration link. About Maxim Group LLC Maxim Group LLC is a full-service investment banking, securities and wealth management firm headquartered in New York. The Firm provides a full array of financial services including investment banking; private wealth management; and global institutional equity, fixed-income and derivatives sales & trading, equity research and prime brokerage services. Maxim Group is a registered broker-dealer with the U.S. Securities and Exchange Commission (SEC) and the Municipal Securities Rulemaking Board (MSRB) and is a member of FINRA SIPC, and NASDAQ. To learn more about Maxim Group, visit About ImmunoPrecise Antibodies Ltd. ImmunoPrecise Antibodies Ltd. is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the discovery and development of therapeutic antibodies and is known for solving complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the 'IPA Family'). View source version on CONTACT: Investor Relations Contact Louie Toma, CPA, CFA Managing Director [email protected] KEYWORD: UNITED STATES NORTH AMERICA CANADA TEXAS INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES TECHNOLOGY SOFTWARE ARTIFICIAL INTELLIGENCE PHARMACEUTICAL BIOTECHNOLOGY SOURCE: ImmunoPrecise Antibodies Ltd. Copyright Business Wire 2025. PUB: 05/20/2025 08:28 AM/DISC: 05/20/2025 08:27 AM
